New insight into the molecular drug target of diabetic nephropathy

Research output: Contribution to journalReview articlepeer-review

23 Citations (Scopus)


Diabetic nephropathy (DN) lowered quality of life and shortened life expectancy amongst those affected. Evidence indicates interaction between advanced glycation end products (AGEs), activated protein kinase C (PKC) and angiotensin II exacerbate the progression of DN. Inhibitors of angiotensin-converting enzyme (ACEIs), renin angiotensin aldosterone system (RAAS), AGEs, and PKC have been tested for slowing down the progression of DN. The exact molecular drug targets that lead to the amelioration of renal injury in DN are not well understood. This review summarizes the potential therapeutic targets, based on putative mechanism in the progression of the disease.

Original languageEnglish
Article number968681
JournalInternational Journal of Endocrinology
Publication statusPublished - 2014


Dive into the research topics of 'New insight into the molecular drug target of diabetic nephropathy'. Together they form a unique fingerprint.

Cite this